Latin America Diabetes Care Devices Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Latin America Diabetes Care Devices Market Overview

Diabetes care devices are advancing with improved technologies that strengthen disease monitoring, optimize treatment strategies, and enhance patient engagement. The market was valued at USD 5.20 Billion in 2025. The growing healthcare modernization is supporting wider adoption throughout the region. The market is driven by increasing chronic disease prevalence, expanding healthcare infrastructure, greater investment in medical technologies, and improving access to diabetes care solutions.

Latin America Diabetes Care Devices Market Growth Analysis and Key Influencers

Latin America Diabetes Care Devices Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Latin America Diabetes Care Devices Market Growth Drivers

Rising Adoption of AI-Enabled Continuous Glucose Monitoring Solutions is Accelerating the Market Value

The increasing adoption of advanced continuous glucose monitoring devices integrated with artificial intelligence is strengthening the market by improving diabetes management, treatment adherence, and patient outcomes. Predictive glucose monitoring and digital health platforms are encouraging wider acceptance of connected diabetes care devices across healthcare systems. For instance, in September 2025, Roche expanded the availability of its AI-enabled Accu-Chek SmartGuide CGM integrated with the mySugr app across Europe, Latin America, and Asia-Pacific, extending planned access to more than 30 countries. This expansion reflects the growing demand for intelligent diabetes care solutions and is expected to support the long-term value of the market.

Latin America Diabetes Care Devices Market Restraints

High Cost of Advanced Diabetes Care Devices Continues to Limit the Market Expansion

The high cost of advanced diabetes care devices, particularly continuous glucose monitoring systems and insulin delivery technologies, remains a significant challenge for the market. Limited reimbursement coverage, affordability concerns, and unequal healthcare access across several countries restrict the widespread adoption of these innovative devices. As a result, many patients continue to rely on conventional monitoring methods, slowing the penetration of advanced diabetes management technologies and limiting the overall expansion of the market.

Latin America Diabetes Care Devices Market Opportunities

Expanding Access to Advanced Diabetes Therapies Creates New Potential for the Market

The growing partnerships to improve access to advanced diabetes therapies are creating favorable conditions for the market by encouraging broader adoption of diabetes management solutions and complementary care devices. The increasing availability of innovative treatment options is expected to strengthen demand for glucose monitoring and insulin delivery technologies. For example, in April 2024, Biocon Limited entered an exclusive licensing and supply agreement with Biomm S.A. to commercialize generic semaglutide in Brazil, expanding access to advanced treatment for adults with type 2 diabetes. Such strategic collaborations are expected to create significant long-term opportunities for the market.

Latin America Diabetes Care Devices Market Trends

The market is witnessing several trends, including AI-enabled diabetes management, connected drug delivery, and patient-centric care technologies.

Growing Adoption of Advanced Drug Delivery Technologies is Enhancing the Market Growth

The increasing adoption of patient-friendly drug delivery technologies is reshaping diabetes management by improving dosing accuracy, convenience, and treatment adherence. These innovations are supporting the broader integration of connected diabetes care solutions across the healthcare ecosystem. For instance, in July 2026, BD and EMS collaborated to launch semaglutide therapy in Brazil using the BD Vystra™ injection pen platform, supporting reliable and user-friendly self-injection. This trend is expected to strengthen technological advancement and enhance the long-term value of the market.

Latin America Diabetes Care Devices Market Share

Type 2 Diabetes Segment is Expected to Lead the Market Expansion

The market is segmented by disease type into Type 1 Diabetes and Type 2 Diabetes. Among these, Type 2 Diabetes is expected to account for the largest market share owing to its substantially higher disease burden and increasing demand for long-term glucose monitoring and insulin delivery devices. According to Marcio Krakauer et al., 2024, Type 2 diabetes mellitus represents one of the most significant public health challenges across Latin America, with millions of adults living with the condition. The rising prevalence of Type 2 diabetes is expected to sustain strong demand for diabetes care devices and support continued market expansion.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Latin America Diabetes Care Devices Market Analysis by Region

The regions included in the report are Brazil, Argentina, Mexico, and others. Among these, Brazil is expected to dominate the market due to its large diabetic population, expanding clinical research activities, and increasing adoption of innovative diabetes technologies. For instance, in March 2026, Glucotrack announced successful progress from its first-in-human continuous blood glucose monitoring clinical study conducted in São Paulo, Brazil, supporting the advancement of its implantable glucose monitoring technology toward United States clinical trials. Such advancements reinforce Brazil's leadership and are expected to drive continued market growth across the region.

Leading Players in the Latin America Diabetes Care Devices Market

Latin America Diabetes Care Devices Market Segmentation

Key Questions Answered in the Latin America Diabetes Care Devices Market Report

• What was the Latin America diabetes care devices market value in 2025?
• What is the Latin America diabetes care devices market forecast outlook for 2026-2035?
• What are the major factors aiding the Latin America diabetes care devices market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major diabetes care devices market trends?
• Which product type is expected to dominate the market segment?
• Which disease type is projected to lead the market segment?
• Which patient care setting is anticipated to drive the market segment?
• Who are the key players involved in the Latin America diabetes care devices market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews conducted with 30+ endocrinologists, diabetologists, diabetes educators, hospital procurement managers, distributors, and healthcare policymakers across Brazil, Mexico, Argentina, and other Latin American countries, including key opinion leaders (KOLs) affiliated with regional diabetes and endocrinology associations.
• Secondary Research: Peer-reviewed publications from Diabetes Care, The Lancet Diabetes & Endocrinology, and BMJ Diabetes Research & Care; regulatory information from ANVISA, COFEPRIS, and other regional health authorities; clinical trial data from ClinicalTrials.gov; epidemiological data from the WHO, International Diabetes Federation (IDF), PAHO, and national health agencies; along with company annual reports, investor presentations, product portfolios, press releases, and official company websites.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling and validated through expert review, industry feedback, and cross-verification with multiple secondary sources.